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Summary Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced
breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen
(T) +AG, or T+AG+danazol. The mean level of prolactin was higher, and there were more individuals with
levels of prolactin O 500mIUI-l, in the group of patients who did not respond to treatment. Of the patients
whose disease progressed, those with prolactin levels O 500 mIU - had a significantly shorter survival. It
appears that high prolactin levels indicate a poor prognosis to endocrine therapy and the probability of a
shorter than average survival time.
There are numerous reports in the literature of
investigations of relationships between prolactin
and various aspects of breast cancer (See reviews by
Smithline et al., 1975; Nagasawa, 1979). The
majority of these have concentrated on a possible
aetiological association between the incidence of
breast cancer and abnormalities in prolactin
secretion. Many have found suggestive but by no
means definitive evidence of such an association.
There has also been a marked lack of success in
trials of drugs which were aimed solely at
suppression of prolactin levels in patients with
advanced breast cancer (European Breast Cancer
Group, 1972; Engelman et al., 1975). This is despite
the frequent occurrence of prolactin receptors on
the tumour cells (Di Carlo & Muccioli, 1979).
Overall, these studies have suggested that there is
no major role for prolactin in human breast cancer.
There are, however, a number of reports which
conclude that high serum prolactin levels in
advanced breast cancer patients are an indicator of
a poor prognosis to both endocrine (Willis et al.,
1977; Ragaz et al., 1982) and cytotoxic (Nagel et al.,
1982) therapy. Suppression of these high prolactin
levels was associated with an increased response to
cytotoxic therapy (Nagel et al., in preparation). We
have already reported (Harris et al., 1983) that
there were few responders to aminoglutethimide
therapy among those patients who had high
prolactin levels whilst on treatment. In this report
we have examined the relationship in
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postmenopausal patients with advanced breast
cancer between pretreatment serum prolactin
concentrations and (1) the response to one of 3
endocrine treatments and (2) the length of survival
of the patients.
Patients and methods
All patients were post-menopausal or had been
previously treated with oophorectomy and all had
histologically-proven advanced breast cancer. Before
entering their respective course of endocrine
treatment, each patient had a blood sample taken
between 9.30 and 11.00 am, and the resulting serum
was frozen at -20°C until assayed. One hundred
and thirty-five patients were treated according to
one of the following three protocols, and their
response to therapy was assessed according to
standard UICC criteria (Hayward et al., 1977).
(1) Aminoglutethimide (AG), 55 patients
No endocrine treatment had been given to the
patients for at least 4 weeks. Thirty-three patients
had previously been treated with tamoxifen (T), 5
patients had been oophorectomized, and 2 patients
had taken T as well as being oophorectomized.
Fifteen patients had no previous endocrine therapy.
Patients were treated with increasing doses of AG
over the first month. By the end of this time the
dosage had increased to 250mg four times a day
(q.d.s.) or to a lower maximum tolerated dose. They
remained on this dose for the duration of their AG
treatment. Additionally all patients received 20mg
hydrocortisone twice daily (b.d.).
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(2) Tamoxifen +Aminoglutethimide (TAG),
43 patients
No previous endocrine therapy had been given to
the patients before starting TAG. Drug dosages
were: tamoxifen 10mg b.d., hydrocortisone 20mg
b.d. and aminoglutethimide 250mg three times daily
(t.d.s.) for the first 2 weeks increasing to 250mg
q.d.s. providing the drug was tolerated.
(3) Tamoxifen +Aminoglutethimide +Danazol (TAD),
37patients
No previous endocrine therapy had been given to
patients treated with TAD. Patients received
tamoxifen 10mg b.d., aminoglutethimide 250mg
t.d.s., danazol 100mg t.d.s. and hydrocortisone
20 mg b.d.
Patients were maintained on their respective
treatment until their disease progressed, at which
stage they were treated with whatever alternative
form of therapy seemed appropriate to the clinician.
Prolactin assay:
Prolactin was measured by double antibody
radioimmunoassay. 125I-labelled prolactin was
obtained from North East Thames Regional
Immunoassay Unit. All other reagents were WHO
matched reagents and were provided by the WHO
Special Programme of Research in Human
Reproduction. The assay was performed according
to WHO recommended methodology (WHO, 1982),
and used IRP 75/504 as standard. The cross-
reaction to human growth hormone was 1.5% and
the intra- and inter-assay coefficients of variation
were <7% and <10% respectively.
Results
The prolactin results have been grouped in Figure 1
and Table I according to the treatment which the
patients received and according to the course of the
patients' disease on treatment. The prolactin levels
found in the whole group of patients had a skewed
distribuition: the majority of patients had
concentrations between 100 and 300mIU1-1 but
there was a long diminishing "tail" with higher
levels. This approximates to the logarithmic
distribution of prolactin found in the normal
population (Jeffcoate, 1978). For this reason, the
prolactin levels have been plotted in Figure 1 on a
logarithmic scale and the same results have been
expressed in Table I as geometric means and
coefficients of variation. Statistical comparisons
between groups of results were performed on
logarithmically-transformed data using Student's t-
test. The results of these tests are shown in Table I.
In the individual treatment groups the only
significant difference apparent was in the AG group
where prolactin levels were significantly higher in
the groups of patients with progressive disease than
in the combined group that responded or had
stable disease. When the results from the 3 treatment
groups were combined, prolactin levels were found
to be significantly higher in the group of patients in
whom the disease progressed than in the group that
responded or had stable disease.
The combined data from the 3 treatment groups
was also examined for differences between the
response groups in the frequency of occurrence of
high levels (defined below) of prolactin. Significantly
more patients had a prolactin level >500mIUI-
Table I Mean pretreatment prolactin levels according to treatment and response groups
Study group AG TAG TAD Overall
Response group R R+SD PD R R+SD PD R PD R R+SD PD
Geometric xT 202 196 278 196 206 203 176 287 191 193 255
Geometric CV (%) 70 68 84 92 82 107 100 132 85 80 105
n 15 19 36 14 19 24 15 22 44 53 82
t-test
probability
R vs PD 0.090 >0.100 0.072 0.026
(R+SD) vs PD 0.038 >0.100 0.021
R, responders; S.D., stable disease; P.D., progressive disease; CV, coefficient of variation.
t-tests were performed on logarithmically transformed data.PROLACTIN IN BREAST CANCER 765
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Figure 1 Pretreatment prolactin level and patient response. The prolactin levels are plotted on a logarithmic
scale. R =responder, S.D. =stable disease, P.D. =progressive disease. The overall column shows the combined
data from all 3 treatments.
in the group that developed progressive disease
(15/82) than in either the group who showed
objective response (2/44; x2 P <0.05) or the
combined group of those showing objective
response or stable disease (2/53; P <0.02).
Significant differences were similarly found by
discrimination at >500, >520 and >540mIU
prolactin - 1'.
The combined data for patients whose disease
progressed was analysed for any prognostic
significance of the pretreatment prolactin levels.
This possible relationship is examined in Figure 2
where pretreatment prolactin level is plotted against
length of patient survival from time of sample and
in Figure 3 where the actuarial survival curves of
the patients from time of sample are shown grouped
according to pretreatment prolactin level (<500 or
> 500mIUl1-). The survival curves were found to
be significantly different (P = 0.006, logrank test).
The median survival (both actual and actuarial) for
those patients with prolactin levels >500mIUl-1
was found to be 5.3 months whilst for those with
prolactin levels <500mIUl-' it was found to be
10.0 months.
In those patients who did not respond to
treatment and went on to die within 6 months of
time of sample, the known sites of metastatic
disease (also at time of sample) were compared
between patients with prolactin levels
<500mIU- 1 and those with levels >500mIUl1
(Table II). There was no significant difference in the
mean number of involved sites per patient between
the 2 groups (P>0.2, t-test). Similarly there was no
significant difference between the 2 groups in the
incidence of particular sites of disease (X2 =3.4,
d.f.=5, P ,0.5).
30001-
1000I-
500 E
C)
a-
200 F-
1001-
70
I-
* A-
A
A *-
A*-
A
*-
A.
*-- A A*-
A---
A*A--
s A
I I I I
A
.
A766 M. DOWSETT et al.
2500
2000F
1500 -
10001
U
U
.
.
.
U
a
*
U M
No
-
* a . -
Uso in
5
.
U
* m :
* U
* U.. * * I..
10
Survival (months)
Figure 2 Pretreatment prolactin level and patient survival. Only those patients who progressed on treatment
are plotted. Arrows indicate that an individual was alive at the time of data analysis.
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Figure 3 Actuarial survival of patients according to
pretreatment prolactin level. Only those patients who
progressed on treatment are plotted. A: prolactin
>500mIUl-1, B: prolactin <500mIU P- 1. Logrank
test shows the 2 curves to be significantly different
(P =0.006).
Discussion
The interpretation of the results obtained in this
study depends on the confidence with which a
single prolactin estimate between 9.30 and 11.00 am
represents the prolactin status of the patient. The
defined time period was chosen to avoid major
variation due to the diurnal rhythm of prolactin. By
9.30 am, the fall of prolactin levels from their
nocturnal, sleep-induced peak has reached a plateau
(Cowden et al., 1979). It has been suggested that
artefactual high prolactin levels may occur due to
pulsatile release (Ehara et al., 1973) or stress at
venepuncture (Koninckx, 1978). Indeed such
arguments have led to the suggestion (Jeffcoate,
1978) that serial blood sampling would be more
advantageous in the estimation of prolactin status.
However, a number of investigations have
concluded that venepuncture rarely, if ever, induces
prolactin release (Koninckx, 1978; Cowden et al.,
1979; Pearce et al., 1980) and that frequent
sampling does not improve the value of a result
(Pearce et al., 1980; Moult et al., 1981). These
studies suggest that the results obtained in the
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Table II Frequency of metastatic site involvement in progressive disease patients surviving 6
months or less, with discrimination according to prolactin level
Number ofpatients with site involved Total Mean no.
no. of ofinvolved
Soft Lymph involved sites/patient
Patient group tissue nodes Lung Bone Pleura Liver sites +s.d.
Prolactin
<500mIUl 1
(n=21) 12 6 7 12 4 6 47 2.24
+0.94
Prolactin
500mIUI
(n=11) 7 1 6 6 1 6 27 2.45
+0.93
Total number
of patients with
site involved 19 7 13 18 5 12 74 2.31
+0.93
present report may be viewed with confidence.
There are, however, a variety of drugs which can
affect prolactin release (Fluckinger, 1972) and it is
unfortunate that we were unable to take account of
this.
The 3 endocrine treatments investigated were all
aimed at suppression of oestrogen synthesis either
alone (AG) or in addition to inhibition of oestrogen
action (TAG and TAD). The combined results for
the 3 therapeutic regimes demonstrated that the
mean level of prolactin was higher in the patients
with progressive disease and that a high
pretreatment serum prolactin level was an indicator
of a low probability of response. These findings are
supported by a number of studies of patients whilst
on T or AG treatment, in which high levels of
prolactin were observed significantly more frequently
in non-responders to treatment (Willis et al., 1977;
Ragaz et al., 1982; Harris et al., in preparation).
In the present analysis of data, differences were
tested between both responders versus progressive
disease and responders plus stable disease versus
progressive disease. This is appropriate since it has
been found by our group that the survival of
patients with stable disease on endocrine therapy is
similar to that of patients who show disease
remission (Harris et al., 1982).
We examined the length of survival of the non-
responders to assess whether besides being an
indicator of a poor likelihood of response to
endocrine therapy, high serum prolactin levels
might have some further significance for disease
progression. The actuarial survival analysis shows
clearly that non-responders with prolactin levels
> 500mIU -' had a lower chance of a long
survival than those with lower prolactin levels. It is
of concern that this may have been a result of
differing severity of disease at the time of sample,
such that those patients with particularly advanced
disease might have a short survival time combined
with a stress-related increase in prolactin levels
(Noel et al., 1972). Stress is extremely difficult to
quantify, but in this situation it would be expected
to relate to tumour load and/or site of metastatic
spread. The majority of patients with prolactin
levels 5OOmIUI-1 died within the first 6 months
of treatment, but there were nearly twice as many
who died within the same period who had lower
levels of prolactin. The clinical data were analysed
to see if there was any evidence for patients with
high prolactin levels in this group of short-term
survivors, having greater tumour load (as reflected
by number of involved sites of disease) at time of
sample than those short-term survivors with low
prolactin. The results showed that the mean
number of involved sites per patient was similar in
the high and low prolactin groups. There was also
no difference between the two groups in the
occurrence of particular sites of disease. Thus from
these analyses there is no evidence to suggest that
the high prolactin levels in short-term survivors
were as a result of stress, which was related to
either tumour burden or site of metastatic spread.
An alternative explanation for the relationship
between prolactin levels and both endocrine
response and patient survival is that some breast768 M. DOWSETT et al.
carcinomas may possess a growth response to
prolactin. It appears that few, if any, breast tumours
are totally dependent on prolactin, since clinical
trials of bromocriptine and L-dopa have
demonstrated virtually no objective responses
(European Breast Cancer Group, 1972; Engelsman
et al., 1975). However, it may be that some breast
tumours possess a joint dependence on oestrogen
and prolactin similar to that found in some 7,12-
dimethylbenz(a)anthracene-induced tumours in rats
(Leung et al., 1975). Thus, therapy aimed solely at
inhibition of oestrogen synthesis and/or action may
be insufficient to elicit the regression of some
tumours, whilst additional anti-prolactin treatment
may cause regression. Support for this concept
comes from the work of Ward (1977) who noted
that 14/36 patients with advanced breast cancer
whose disease had progressed on treatment with
tamoxifen alone subsequently responded to
combined treatment with bromocriptine and
tamoxifen.
It is also of interest that the studies of Pearson &
Manni (1981) and Hayward et al. (1970) both show
that hypophysectomy was of greater benefit than
treatments designed solely at countering tumour
stimulation by oestrogen. The studies suggest that
besides those hormones which stimulate oestrogen
synthesis, there may be a factor of pituitary origin
(possibly prolactin) which stimulates the growth of
breast tumours. We feel that the present study and
the reports cited justify a thorough investigation of
combined antiprolactin/antioestrogen therapy.
We are grateful to the WHO Special Programme of
Research in Human Reproduction for the provision of
assay reagents. We also thank Mrs. Lorna Carr and Mrs.
Jane Hunt for their help in the analysis of patient records.
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